United States Cancer Biomarkers Market - Growth, Trends and Forecasts (2016-2021)

1. INTRODUCTION

1.1 Objective

1.2 Key findings and observations

1.3 Research methodology

1.4 Market stakeholders

  2. EXECUTIVE SUMMARY

  3. MARKET OVERVIEW

3.1 Definition of the market

3.2 Market growth estimation

3.3 Market size estimation

3.4 Classification of Cancer biomakers

3.5 Technologies used in Identifying cancer biomakers

3.6 Market Dynamics

3.6.1 Market Drivers

3.6.1.1 Non invasive technologies

3.6.1.2 Increased survival rates

3.6.1.3 Enhanced accuracy and Speed of diagnosis

3.6.1.4 Streamlined drug delivery process

3.6.1.5 Helps in FDA approval of drugs

3.6.1.6 Boost in government and Private funds for biomarkers discovery

3.6.2 Market Restraints

3.6.2.1 High cost of diagnosis

3.6.2.2 Reimbursement issues

3.6.2.3 Need for immediate processing

4 Biomarkers Indication Market

4.1 Oncology Biomarkers Market

4.2 Cardiology biomarkers market

4.3 Neurology biomarkers market

4.4 Others Indication Biomarkers Market

4.5 Disease types

4.6 Renal failure

4.7 Arthritis

4.8 Tuberculosis

4.9 Diabetes

  5. North America market segmentation

5.1 Market segmentation, By type of applications

5.1.1 Risk Assesment

5.1.2 Devlopment of molecular diagnostics

5.1.3 Disese diagnosis

5.1.4 Drug discovery and development

5.1.5 Drug formulation

5.1.6 Forensic application

5.1.7 Others(DNA fingerprinting and others)

5.2 Market segmentation, By Services

5.2.1 Sample preparation

5.2.2 Assay developement

5.2.3 Biomakers validation and testing

5.3 Market segmentation, By Geography

5.3.1 North America

5.3.1.1 US

5.3.1.2 Canada

6. Cancer Biomarkers Market

6.1 Introduction

6.2 Oncology Biomarkers Market

6.3 Oncology biomarkers Discovery market

6.3.1 Genomics

6.3.2 Proteomics

6.3.3 Metabolomics

6.3.4 Transcriptomics

6.3.5 Other Omics

6.3.6 Imaging

6.4 Cancer Biomarkers Diagnostic Market

6.4.1 Immunohistochemical (IHC) tests

6.4.2 Molecular (DNA and genomic) diagnostic assays

6.4.3 Genetic and genomic markers

6.4.5 Proteomics

6.4.6 Flow cytometry

6.4.7 Stem cell markers

6.4.8 Monoclonal antibodies

6.4.9 Pharmacogenomics

6.4.10 DNA microarrays

6.4.11 IVD multivariate index assays (IVDMIA)

7. Competitive Landscape

7.1 Introduction

7.2 New product launches

7.3 Market strategies

7 .4 Agreements, Partnerships & expansion

7 .5 Mergers and Acquisitions

 

7.6 Market Share Analysis 

8. Key Vendors In Market

8.1 Abbott Laboratories

8.2 Affymetrix Inc

8 .3 Agilent Technologies

8 .4 Analytical Technologies

8 .5 Analytical Biological

8 .6 Applied Neurosolutions, Inc

8.7 Bristol-Myers Squibb

8 .8 Genomic Health Inc.

8 .9 Merck & Co, Inc

8.10 Pfizer, Inc

9. Appendix

9 .1. Abbreviations

9 .2. Sources

9 .3. Bibliography

9 .4. Disclaimer